ALNEV Share Price Performance
€0.0002
-3.60 (-99.99%)
Price €0.0002
Share Pricen/a
Neovacs S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ALNEV Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Neovacs S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -9.14
- -1,459.28%
- -2,186.98%
- 0.9%
About ALNEV
- Founded
- 1993
- Employees
- 16
- CEO
- WebsiteView website
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.